Trial Profile
A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Testing Clofarabine (NSC# 606869) in the Very High Risk Stratum
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 09 Apr 2021
Price :
$35
*
At a glance
- Drugs Clofarabine (Primary) ; Cyclophosphamide (Primary) ; Etoposide (Primary) ; Hydrocortisone sodium succinate (Primary) ; Pegaspargase (Primary) ; Antineoplastics; Cytarabine; Cytarabine; Cytarabine; Daunorubicin; Dexamethasone; Dexamethasone; Doxorubicin; Folinic acid; Folinic acid; Mercaptopurine; Methotrexate; Methotrexate; Methotrexate; Methylprednisolone; Methylprednisolone; Prednisone; Prednisone; Tioguanine; Vincristine
- Indications Down syndrome; Leukaemia; Osteonecrosis; Pain; Precursor B-cell lymphoblastic leukaemia-lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
- 09 Apr 2021 This trial has been discontinued in Ireland as per European Clinical Trials Database record
- 19 Dec 2017 Toxicity results published in the Cancer
- 02 Mar 2017 This trial has been suspended in Ireland as per European Clinical Trials Database record.